The composite number needed to treat for semaglutide in populations with overweight or obesity and established cardiovascular disease without diabetes
Patients taking diabetes medications or blood pressure medications should be especially careful because weight loss and appetite changes may alter medication needs
As healthcare systems prioritize chronic disease management, GLP-1 receptor agonists are positioned to remain a critical component of treatment protocols
A recent study, for example, supports the concept of combining liraglutide therapy for obesity with exercise to improve the maintenance of weight reduction and metabolic parameters
However, it should be avoided if diarrhea is already a problem
Numerous gastrointestinal conditions, such as irritable bowel syndrome, inflammatory bowel disease, and small intestinal bacterial overgrowth, have been associated with dysbiosis (an imbalance or disruption in the composition and diversity of the gut microbiome) [111]